Additionally, FGFR1 IIIc and FGFR2 IIIc are frequently co-expressed with their complementary ligands—FGF2 and FGF9 in primary NSCLC tumors [142]. This evidence concerns the gene FGF9 and non-small cell lung carcinoma.